Trial Profile
Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Feb 2020 Planned End Date changed from 1 Jul 2019 to 1 Jul 2021.
- 04 Feb 2020 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2021.
- 28 Jul 2019 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.